Regenerative medicine is a recently developed multidisciplinary discipline aimed to replace or restore normal function of cells, tissues, and organs that are damaged by disease. Regenerative Medicine is a branch of translational research in tissue engineering and molecular biology that deals with the “process of replacing, engineering or regenerating human cells, tissues or organs to restore or establish normal function”. The promising field of Regenerative Medicine is working to restore structure and function of damaged tissues, bone, cartilage, ligaments, muscles and organ function. With the use of RICHGEN undifferentiated pluripotent extra cellular matrix it is possible to regenerate damaged tissues by stimulating the body to heal itself. The RICHGEN FDA registered products are researched, tested, developed and tested again like no other regenerative cellular product on the market today, in a regularly FDA inspected laboratory, located in Florida.
RICHGEN unrivaled tissue allograft products are undifferentiated pluripotent with all 50 supporting growth factors, cytokines, collagens and other regenerative components. Cord blood cells are only multipotent and do not have the growth factors so it is best to use with RICHGEN I for a complete regenerative therapy. So, undifferentiated pluripotent cells with all supporting growth factors is much more potent than multipotent stem cells that average as little as 2 – 3 % in growth factors.
In addition, it is important to know that RICHGEN proprietary cryogenic freezing process the inner cellular components are not frozen as other manufacturers do. RICHGEN outer membrane biomaterials are cryo frozen but not the inside of the tissue allograft due to our incredible private biotech process. So when thawed they are more reliable than other brands and effective being a combination product of four materials, therefore, will regenerate better and provide considerable outcomes in comparison.
Amniotic placental tissue is derived from a combination of post birth human amniotic fluid and membrane. Enriched RICHGEN products also contain beneficial Wharton’s jelly from the cord and placental tissue. These materials combined powerfully contain growth factor proteins, collagen, hyaluronic acid and extracellular matrix that work together to increase the patient’s own healing response and accelerate the regeneration of healthy, strong tissue to function.
Wharton’s jelly is a gelatinous cushioning substance in the umbilical cord that provides support to the umbilical vein and arteries. The cushioning and protective elements from Wharton’s jelly consist of a network of structural biomolecules, pericytes, mesenchymal stem cells, cytokines, chemokines and growth factors as the main regenerative components.
Wharton’s Jelly is processed from donated human tissue from full term Cesarean deliveries and is regulated as a human cell, tissue, or cellular or tissue-based product (HCT/P) under 21 CFR Part 1271 and Section 361 of the Public Health Service Act. Medical and social histories of the donors are obtained in advance and tissues are procured, processed, and tested in accordance with standards established by FDA requirements to minimize potential risks of disease transmission to recipients. Infectious disease testing is performed at a certified laboratory in accordance with the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and 42 CFR part 493.
Sourced from the minimally manipulated human tissue allograft derived from the Wharton’s Jelly of the umbilical cord lining maintains the undifferentiated pluripotent mesenchymal (MSC) counts. It is processed to preserve the high levels of cytokines, growth factors, proteins and structural integrity of Wharton’s jelly for homologous use and cryogenically preserved.
All donors of pre-planned Caesarean births are carefully reviewed for health and social histories. The donor tissues are then minimally manipulated abiding by FDA 21CFR part 1271/PHS 361. Please see our Compliance page for safety regulations. RICHGEN I and RICHGEN II products do not have any red blood cells in the manufacturing process. There have been no adverse reactions to our products from our tissue bank in 10 years of research, clinical study and patient use.
Our physicians do not recommend this method due to the adverse reactions of blindness, stroke and infection in many cases. The discomfort of the surgery during and post for weeks is also a concern. Physicians now are simply thawing our RICHGEN premiere product in three minutes and injecting, applying or infusing as needed. There have been no adverse reactions in ten years with our tissue bank products.
Age greatly reduces the quality of one's own cells, so surgery extraction is no longer recognized as the leading edge choice. RICHGEN is by far superior to obtain the best results, is non-invasive and does not require hours of surgery. Our regenerative therapy allows your own body to respond naturally.
RICHGEN amniotic fluid, membrane, placenta and Wharton’s jelly been demonstrated clinically to provide an effective option for treating various conditions with no adverse reactions.
RICHGEN undifferentiated pluripotent stem cells contain multiple properties and key growth factors that create an environment for tissue regeneration, function and acceleration of the healing process. It provides anti-inflammatory, anti-microbial, anti-tumorigenic effect on injured tissue and regenerates any body layer to create a healthy environment for relieving pain and developing new healthy tissue growth or bone. Consult with your physician to determine if this advance in medicine therapy is right for you.
Treatments of this regenerative therapy are available for those suffering from musculoskeletal conditions, respiratory problems, acne, COPD, lyme, cancer, dental, lupus, Parkinson's, joint pain, damaged ligaments and tendons, degenerative disc disease and osteoarthritis, issues of inflammation or many other types of chronic pain, diabetes scarring and many other indications. RICHGEN is also useful for autoimmune and systemic insufficiencies as well as for overall wellbeing and longevity.
Yes, cellular biologics contain key regenerataive components that may help to restore the damaged tissue so surgery is prevented and not required. A physician may also determine that treatment post-surgery is appropriate. Consult your physician for a proper diagnosis and treatment protocol for your condition(s).
The cord blood cells are not pluripotent, they do not contain growth factors, do not differentiate what body layer needs healing and truly only average a low only 2% MSCs (medicinal signaling cells) where all the power is. Also, they are extremely perishable. In fact, almost all the hematopoietic stem cells being administered are dead cells as are fully frozen cells that other brands offer. So while they claim to be regenerative, they will not compare in results to RICHGEN — the brand of choice today. In addition, hematopoietic stem cells are not effective as a regenerative medicine for joints, bone, cartilage, organs, nerves, etc. Only pluripotent MSC (mesenchymal stem cells) medicinal signaling cells have proven to be beneficial for the physical body and to cascade for better coverage. That is why RICHGEN is called the Holy Grail of new medicine. MSC’s are derived from non-blood, post-birth tissues. Enriched RICHGEN is undifferentiated pluripotent, produced from placenta, Wharton’s jelly from the cord, amniotic fluid and amnion membrane. No other lab produces such a synergistic and sophisticated regenerative allograft product.
Yes, it is safe. Amniotic fluid is excreted through the whole body surface in the first 14-20 weeks of development. There is no urea (that would be seen in kidney produced urine, in fetal development the kidneys are not producing amniotic fluid). Essentially every article written on the clinical uses of amniotic fluid as a therapy speaks to its safety profile. There have been no adverse reactions to the RICHGEN product. Patients have only experienced regeneration.